The Saginaw Heritage grad celebrated his 25th birthday Saturday with a 5-0 shutout of Boston, hitting the 100-mph mark twice.

Spencer Schwellenbach struck out 11 in 6 1/3 innings on his 25th birthday to help the Atlanta Braves beat the Boston Red Sox ...

The Braves’ young star starter put together a brilliant start against Boston and the offense backed him up sufficiently for a ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

GSK plc and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, announced that they have entered ...

GSK has announced that it will be acquiring Boston Pharmaceuticals’ phase 3-ready liver disease candidate in a deal worth up to $2bn. Efimosfermin alfa is an investigational drug in clinical ...

GSK GSK2.07%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...